About Joshua Allen-Dicker

Joshua Allen-Dicker

All posts by Joshua Allen-Dicker

Keeping up with Novel Hepatitis C Genotype 1 Trials

• May 14th, 2014

This week’s NEJM features two studies (ION-1 and ION-3) that examine ledipasvir, a NS5A inhibitor, and sofosbuvir, a nucleotide polymerase inhibitor, for previously untreated HCV infection.  A recent search of the New England Journal of Medicine archives for the term “HCV” returned 45 original research articles from the last 5 years. For many of us,… Read More…


Surgery Versus Watchful Waiting for Localized Prostate Cancer: the 18-Year Debate

• March 5th, 2014

In 2013, over 238,000 men were diagnosed with prostate cancer in the United States.  Each of these patients and their physicians has undoubtedly been faced with a vexing series of decisions: What should I do next?  Will the treatment help, or will the cure be worse than the disease?  The publication of the 18-year follow-up… Read More…


The Case Against Renal Stenting for Treatment of Hypertension and Chronic Kidney Disease

• January 2nd, 2014

Wouldn’t it be great if medicine could borrow from the science behind percutaneous coronary arterial stenting (used over 600,000 times per year in the United States for coronary ischemia) in order to treat a chronic and widespread disease such as hypertension?  The CORAL trial (Cardiovascular Outcomes in Renal Atherosclerotic Lesions), published in this week’s NEJM,… Read More…


Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction

• October 23rd, 2013

If there was a broken-down car on your street blocking traffic, would you rather hire a tow truck to remove it, or hire a bulldozer to smash it into smaller pieces?  Most people might pick the first option, but recent results of the TASTE trial (Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia) suggest that… Read More…


Considering the Data on Novel Anticoagulants

• August 28th, 2013

When a patient in need of anti-coagulation therapy asks about newer, non-warfarin options, physicians often pause.  There is a lot to think about here: recent studies on several different novel anticoagulant drugs, nuances of each trial, and FDA-approved indications for each drug.  For better or for worse, the pause we take to consider anticoagulation options… Read More…